Scancell Holdings PLC has secured UK regulatory approval to run a late-stage trial of its lead drug, iSCIB1+, in advanced melanoma. The phase III registrational study will enroll 550 patients across 90 sites in the US, EU, UK, Canada, and Australia. The trial aims to measure progression-free survival and overall survival, with the goal of supporting an accelerated approval and later full approval. The trial design draws on the earlier phase II SCOPE trial, which found 77% of patients were progression-free at 22 months. Scancell is also pursuing a proposed merger with Neuphoria Therapeutics.

Neuphoria

Scancell Secures UK Approval for Late-Stage Melanoma Trial

Monteverde & Associates PC is investigating Northrim Bancorp, Inc. (NASDAQ: NRIM) over its merger with PBCO Financial Corporation. The firm is also investigating Neuphoria Therapeutics, Inc. (NASDAQ: NEUP) related to its merger with Scancell Holdings plc. Upon completion, Neuphoria shareholders are expected to own 11.1% of the combined company. Monteverde & Associates PC has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report.Monteverde &amp; Associates PC is currently investigating Northrim Bancorp, Inc. (NASDAQ: NRIM) concerning its proposed merger with PBCO Financial Corporation. The firm is also examining Neuphoria Therapeutics, Inc. (NASDAQ: NEUP) in relation to its merger with Scancell Holdings plc. Under the terms of the Neuphoria-Scancell transaction, <a href="http://maadvisor.com/themaadvisor/prnewswire.html?filter=242&amp;rkey=20260723DC11221">hold 11.1% of the combined</a> entity post-merger. Monteverde &amp; Associates PC specializes in representing shareholders in corporate investigations and has a history of recovering significant funds on their behalf. The firm is recognized as <a href="http://maadvisor.com/themaadvisor/prnewswire.html?filter=242&amp;rkey=20260723DC11221">Top 50 Firms 2025</a> ISS Securities Class Action Services Report. For Northrim Bancorp, the firm is seeking to determine whether the merger process has been conducted in the best interests of shareholders. Potential plaintiffs are required to have owned shares prior to the merger announcement and <a href="https://monteverdelaw.com/case/northrim-bancorp-inc/">retain ownership through the conclusion</a> of the transaction. The firm covers all litigation costs and <a href="https://monteverdelaw.com/case/northrim-bancorp-inc/">does not require clients</a> to pay legal fees or expenses, regardless of the outcome. Investors who wish to participate in the investigation are encouraged to contact the firm for further details.

Northrim Bancorp

Northrim Bancorp, Neuphoria Therapeutics, Safety Insurance Group Under Investigation

Scancell Holdings has raised £15.7m from UK investors through its retail share offer, exceeding its £2.3m target. The company plans to merge with US biotech Neuphoria Therapeutics, raising up to $89m to fund a global registrational phase III trial for its lead treatment in advanced melanoma. The new company will be dual-listed and 85.5% owned by Scancell shareholders.Scancell Holdings has successfully raised £15.7 million from UK retail investors through its recent share offer, significantly surpassing its initial target of £2.3 million [1]. The company announced plans to merge with US-based biotechnology firm Neuphoria Therapeutics, creating a combined entity that will pursue a global phase III registrational trial for its lead treatment in advanced melanoma. The merger is expected to <a href="https://example.com">raise up to $89 million</a> in funding to support the trial and further development of the therapy. Under the terms of the proposed merger, the new company will be dual-listed and will see <a href="https://example.com">Scancell shareholders retaining 85.5% ownership</a>. This strategic move aims to leverage the strengths of both companies to advance the development of innovative cancer treatments. The fundraising and merger reflect growing investor confidence in the biotech sector and the potential of Scancell’s pipeline.<img src="https://cdn.ainvest.com/aigc/hxcmp/images/compress-1ce37afbe134d002.png" alt="Scancell Raises £15.7M in UK Retail Share Offer, Exceeds Target">

Scancell Raises £15.7M in UK Retail Share Offer, Exceeds Target

Scancell Holdings PLC, a UK-based oncology research specialist, is set to join the Nasdaq after a reverse takeover with US company Neuphoria Therapeutics. This will grant Scancell access to deeper funding pools and potentially higher valuations for cancer immunotherapy companies. AIM's All-Share index rose 1% over the week, while Celsius Resources Ltd plummeted 96% after a lender seized its stake in the Makilala copper-gold project in the Philippines.Scancell Holdings PLC, a UK-based developer of cancer immunotherapies, is preparing to list on the Nasdaq following a reverse takeover with Neuphoria Therapeutics, a U.S.-based biotechnology company. The move is expected to provide Scancell with greater access to capital and potentially enhance its valuation in a market that has shown <a href="https://example.com">increasing interest in oncology innovation</a>. The reverse merger is a common strategy for companies seeking to expand their financial and strategic opportunities in international markets.Meanwhile, on the London Stock Exchange’s AIM market, the All-Share index recorded a 1% increase over the past week, reflecting <a href="https://example.com">modest gains across the board</a>. In contrast, Celsius Resources Ltd experienced a dramatic decline, with its <a href="https://example.com">share price dropping 96%</a> after a lender took control of its stake in the Makilala copper-gold project in the Philippines. The development highlights the volatility and risk exposure inherent in resource-based equities.

Scancell to List on Nasdaq After Reverse Merger with Neuphoria Therapeutics

Custom Health Holdings Inc (TSX:CHLT) received Buy-rated coverage from Stifel, with a C$12 price target and potential upside to C$18 a share. Analysts highlight the company's pill-dispensing platform that addresses healthcare's expensive headache. 374Water Inc (NASDAQ:SCWO) announced a US Army Corps of Engineers technical report validating its AirSCWO technology, achieving a 99.9993% destruction and removal efficiency for PFAS in aqueous film-forming foam. Royalty Management Holding Corp (NASDAQ:RMCO) disclosed new financing for ReElement Technologies, expanding operations and increasing revenue for Royalty Management. Replenish Nutrients Holding Corp (CSE:ERTH) closed a $7.5 million equity investment from SRC Agrominerals Sales, with a $15 million strategic investment expected to close on August 14, 2026. Scancell Holdings PLC (AIM:SCLP) agreed to an all-share merger with Neuphoria Therapeutics, gaining a Nasdaq listing and access to American investors.Custom Health Holdings Inc (TSX:CHLT) has been assigned a Buy rating by Stifel, with a price target of C$12 per share and potential upside to C$18. Analysts attribute this to the company’s innovative pill-dispensing platform, which addresses a significant cost challenge in healthcare. Meanwhile, 374Water Inc (NASDAQ:SCWO) announced that a technical report from the U.S. Army Corps of Engineers validated its AirSCWO technology, achieving a 99.9993% destruction and removal efficiency for PFAS in aqueous film-forming foam.Royalty Management Holding Corp (NASDAQ:RMCO) revealed new financing for ReElement Technologies, which is expected to expand operations and boost revenue. Replenish Nutrients Holding Corp (CSE:ERTH) has secured a $7.5 million equity investment from SRC Agrominerals Sales, with a <a href="https://www.google.com/goto?url=CAESnQEB7keqTVRdg7gxDrlWk36IbxoRbAUn5TSj8UlhR4mPonk2miXT66jGitWyMSJFE6DeYHaET3Ec0eL5-BAPawTLfinrodnG9bYRLMvryTAOWyts7Qn4aZ5WjIeUUl6KxN-hUIBl7q2tB-hKfLSCU0e08-IYiJTQxljhpJXcV9PzwsWiY_vZIuZgCSU51SkiKce9X93GGK9tbJvOIn4m">$15 million strategic investment anticipated</a> to close on August 14, 2026. Scancell Holdings PLC (AIM:SCLP) has entered into an all-share merger with Neuphoria Therapeutics, facilitating <a href="https://www.google.com/goto?url=CAES0gEB7keqTYnwdB-TkzdQhPdNL3u32eXudSWcUf9ayH6TQFZPl1BugrYxTK8cPHXD-qPWZJXzonqD4VNwomvgC4qjY6Vu0T9VnrFWBlNHC9VVDJEud8SsS5OKNbRGQZoTHTU9rr8-EqlqlMwxKrNJzt5XELJxn1T4QWjxwBnEHEJ1S_RtPlTMBbl5FJ9pkF3bxCHKbxgv7bZR2E6jOqCti96s0P1eouwr86t3tHqiHyDgAMLOwK-AoGPPFzHZp87E1u0uyt1fdcZArhQuf4XwjE0RIc0=">a Nasdaq listing and</a> broader access to U.S. investors.

NEUP News